Medbase drug databases are used as reference databases in largest prospective clinical study so far to study the efficacy of decision support remarks in reducing adverse drug reactions in the elderly. PRIMA-eDS (Polypharmacy in chronic diseases: Reduction of Inappropriate Medication and Adverse drug events in elderly populations by electronic Decision Support), supported by a major EU grant, is a multicenter, ambitious prospective study including 5 universities in 4 different European countries. Drug analyses are done with Duodecim EBMeDS decision support module.
There is a shortage on good quality randomized studies investigating the benefits of decision support modules on the the efficacy and safety of drug therapy. Dr Kari Laine, the CEO of Medbase, is proud that PRIMA-eDS has chosen Medbase drug databases as their reference databases. ‘This is a solid proof of the high scientific quality of the databases’, he adds. Results from PRIMA-eDS are expected in 2-3 years from now.